|
Mar 25
|
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
|
|
Mar 22
|
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
|
|
Mar 22
|
Individual investors account for 41% of Equillium, Inc.'s (NASDAQ:EQ) ownership, while insiders account for 20%
|
|
Mar 4
|
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
|
|
Jan 29
|
15 Cash-Rich Penny Stocks Hedge Funds Are Buying
|
|
Dec 21
|
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
|
|
Nov 8
|
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
|
|
Nov 6
|
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
|
|
Aug 9
|
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 9
|
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
|
|
Apr 24
|
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
|